Compare Vertex Pharmaceuticals Incorporated (VRTX) vs Advanced Drainage Systems Inc (WMS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Vertex Pharmaceuticals Incorporated vs Advanced Drainage Systems Inc — how do they compare? Vertex Pharmaceuticals Incorporated trades at $522.29 (market cap $134.06B), while Advanced Drainage Systems Inc trades at $131.83 (market cap $10.08B). The key difference: Vertex Pharmaceuticals Incorporated is far larger — about 13.3× Advanced Drainage Systems Inc's market cap, and Advanced Drainage Systems Inc pays a 0.6% dividend while Vertex Pharmaceuticals Incorporated pays none. Which is the better fit depends on your goals.
| VRTX | WMS | |
|---|---|---|
Market Cap | $134.06B | $10.08B |
Sector | Health | Industrials |
52-Week High | $557.96 | $175.38 |
52-Week Low | $376.62 | $129.50 |
Enterprise Value | $128.18B | $11.68B |
Dividend Yield | — | 0.6% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Vertex Pharmaceuticals (VRTX) trades at $528.9, down 3.15% on the day, amid a mixed technical and fundamental backdrop. The stock shows a bullish moving average signal but neutral oscillators, with key support at $522. Fundamentally, 2025 revenue reached $12.0B with a strong net income margin of 35%, though recent quarterly EPS results have been mixed. The company recently completed the acquisition of Crinetics Pharmaceuticals, signaling growth ambitions.
The outlook remains positive given analyst consensus favoring a Buy rating (84%) and a $548.78 price target, implying upside. Key opportunities include revenue growth from new drug launches, while risks involve competitive pressures and earnings volatility. The stock's current valuation at a P/E of 30.8 requires sustained execution to justify further gains.
Advanced Drainage Systems (WMS) trades at $133.67, down 1.54% on the day, amid a bearish technical signal. The company has consistently beaten earnings estimates in recent quarters, with Q2 2026 EPS of $2.49 exceeding the $2.10 forecast. Revenue for 2025 was $2.90 billion, with a net income margin of 15.5%. Analyst consensus is a Buy with a $188.20 price target, though technical indicators show selling pressure. Recent news highlights institutional buying and strong Q1 2027 results.
The outlook for WMS is mixed; strong fundamentals and analyst optimism contrast with near-term technical weakness. Investment opportunities include market share gains and acquisition synergies, while risks involve cyclical construction exposure and rising investing cash outflows. The stock's current price offers a potential upside to the consensus target, but investors should weigh execution risks against growth prospects.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. In addition to its focus on cystic fibrosis, Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta-thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using non-opioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Read more on VRTX →About Advanced Drainage Systems Inc
Advanced Drainage Systems Inc is engaged in designing, manufacturing, and marketing thermoplastic corrugated pipe and related water management products in North and South America, and Europe. The company's operating segment includes Pipe
Read more on WMS →
